307 related articles for article (PubMed ID: 8559613)
1. Intravenous cysteamine therapy for nephropathic cystinosis.
Gahl WA; Ingelfinger J; Mohan P; Bernardini I; Hyman PE; Tangerman A
Pediatr Res; 1995 Oct; 38(4):579-84. PubMed ID: 8559613
[TBL] [Abstract][Full Text] [Related]
2. A comparison of the effectiveness of cysteamine and phosphocysteamine in elevating plasma cysteamine concentration and decreasing leukocyte free cystine in nephropathic cystinosis.
Smolin LA; Clark KF; Thoene JG; Gahl WA; Schneider JA
Pediatr Res; 1988 Jun; 23(6):616-20. PubMed ID: 3393396
[TBL] [Abstract][Full Text] [Related]
3. [Intra-leukocyte cystine in cystinosis treated with cysteamine].
Ged C; Jean G; Tete MJ; Broyer M; Kamoun P
Ann Biol Clin (Paris); 1991; 49(9):482-6. PubMed ID: 1789502
[TBL] [Abstract][Full Text] [Related]
4. Long-term treatment of cystinosis in children with twice-daily cysteamine.
Dohil R; Gangoiti JA; Cabrera BL; Fidler M; Schneider JA; Barshop BA
J Pediatr; 2010 May; 156(5):823-7. PubMed ID: 20138296
[TBL] [Abstract][Full Text] [Related]
5. Effects of cysteamine therapy in nephropathic cystinosis.
Yudkoff M; Foreman JW; Segal S
N Engl J Med; 1981 Jan; 304(3):141-5. PubMed ID: 7442733
[TBL] [Abstract][Full Text] [Related]
6. Cysteamine therapy for children with nephropathic cystinosis.
Gahl WA; Reed GF; Thoene JG; Schulman JD; Rizzo WB; Jonas AJ; Denman DW; Schlesselman JJ; Corden BJ; Schneider JA
N Engl J Med; 1987 Apr; 316(16):971-7. PubMed ID: 3550461
[TBL] [Abstract][Full Text] [Related]
7. [Cysteamine in the treatment of cystinosis in children. In vitro and in vivo studies].
Louis JJ; Guibaud P; Dumoulin R; Parchoux B; Zabot MT; Bureau J; Baltassat P; Frederich A; Larbre F
Pediatrie; 1984 Dec; 39(8):619-33. PubMed ID: 6535971
[TBL] [Abstract][Full Text] [Related]
8. Switching from immediate- to extended-release cysteamine in nephropathic cystinosis patients: a retrospective real-life single-center study.
Ahlenstiel-Grunow T; Kanzelmeyer NK; Froede K; Kreuzer M; Drube J; Lerch C; Pape L
Pediatr Nephrol; 2017 Jan; 32(1):91-97. PubMed ID: 27350621
[TBL] [Abstract][Full Text] [Related]
9. Cystinosis: renal glomerular and renal tubular function in relation to compliance with cystine-depleting therapy.
Nesterova G; Williams C; Bernardini I; Gahl WA
Pediatr Nephrol; 2015 Jun; 30(6):945-51. PubMed ID: 25526929
[TBL] [Abstract][Full Text] [Related]
10. Intravenous delivery of cysteamine for the treatment of cystinosis: association with hepatotoxicity.
Bendel-Stenzel MR; Steinke J; Dohil R; Kim Y
Pediatr Nephrol; 2008 Feb; 23(2):311-5. PubMed ID: 17668247
[TBL] [Abstract][Full Text] [Related]
11. Cystinosis. Intracellular cystine depletion by aminothiols in vitro and in vivo.
Thoene JG; Oshima RG; Crawhall JC; Olson DL; Schneider JA
J Clin Invest; 1976 Jul; 58(1):180-9. PubMed ID: 932205
[TBL] [Abstract][Full Text] [Related]
12. [Cysteamine eyedrops for treatment of corneal cysteine deposits in infantile cystinosis].
Gräf M; Grote A; Wagner F
Klin Monbl Augenheilkd; 1992 Jul; 201(1):48-50. PubMed ID: 1513127
[TBL] [Abstract][Full Text] [Related]
13. Population pharmacokinetics and pharmacodynamics of cysteamine in nephropathic cystinosis patients.
Bouazza N; Tréluyer JM; Ottolenghi C; Urien S; Deschenes G; Ricquier D; Niaudet P; Chadefaux-Vekemans B
Orphanet J Rare Dis; 2011 Dec; 6():86. PubMed ID: 22195601
[TBL] [Abstract][Full Text] [Related]
14. Adverse reactions to oral cysteamine use in nephropathic cystinosis.
Corden BJ; Schulman JD; Schneider JA; Thoene JG
Dev Pharmacol Ther; 1981; 3(1):25-30. PubMed ID: 7307866
[TBL] [Abstract][Full Text] [Related]
15. The origin of halitosis in cystinotic patients due to cysteamine treatment.
Besouw M; Blom H; Tangerman A; de Graaf-Hess A; Levtchenko E
Mol Genet Metab; 2007 Jul; 91(3):228-33. PubMed ID: 17513151
[TBL] [Abstract][Full Text] [Related]
16. Corneal crystals in nephropathic cystinosis: natural history and treatment with cysteamine eyedrops.
Gahl WA; Kuehl EM; Iwata F; Lindblad A; Kaiser-Kupfer MI
Mol Genet Metab; 2000; 71(1-2):100-20. PubMed ID: 11001803
[TBL] [Abstract][Full Text] [Related]
17. Effects of oral phosphocysteamine and rectal cysteamine in cystinosis.
van't Hoff WG; Baker T; Dalton RN; Duke LC; Smith SP; Chantler C; Haycock GB
Arch Dis Child; 1991 Dec; 66(12):1434-7. PubMed ID: 1776892
[TBL] [Abstract][Full Text] [Related]
18. Long-term treatment of infantile nephropathic cystinosis with cysteamine.
da Silva VA; Zurbrügg RP; Lavanchy P; Blumberg A; Suter H; Wyss SR; Lüthy CM; Oetliker OH
N Engl J Med; 1985 Dec; 313(23):1460-3. PubMed ID: 4058549
[No Abstract] [Full Text] [Related]
19. Halitosis in cystinosis patients after administration of immediate-release cysteamine bitartrate compared to delayed-release cysteamine bitartrate.
Besouw M; Tangerman A; Cornelissen E; Rioux P; Levtchenko E
Mol Genet Metab; 2012 Sep; 107(1-2):234-6. PubMed ID: 22832073
[TBL] [Abstract][Full Text] [Related]
20. Treatment of cystinosis with cysteamine. A pilot study determining dose and form of application.
Bergonzi E; Herren A; Lavanchy P; Bühlmann C; Wyss SR; Lüthy C; Oetliker O
Helv Paediatr Acta; 1981 Nov; 36(5):437-43. PubMed ID: 7031022
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
